- Home
- FRME vs OGN Comparison
FRME vs OGN Comparison
Compare FRME & OGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FRME | OGN |
|---|---|---|
| Founded | 1893 | 1923 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 1.8B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | FRME | OGN |
|---|---|---|
| Price | $39.65 | $9.74 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 4 | 5 |
| Target Price | ★ $47.33 | $14.10 |
| AVG Volume (30 Days) | 257.4K | ★ 6.3M |
| Earning Date | 01-26-2026 | 02-12-2026 |
| Dividend Yield | ★ 3.66% | 0.83% |
| EPS Growth | ★ 32.99 | N/A |
| EPS | ★ 4.00 | 1.91 |
| Revenue | $649,589,000.00 | ★ $6,301,000,000.00 |
| Revenue This Year | $13.81 | N/A |
| Revenue Next Year | $14.43 | N/A |
| P/E Ratio | $9.83 | ★ $5.02 |
| Revenue Growth | ★ 9.53 | N/A |
| 52 Week Low | $33.13 | $6.18 |
| 52 Week High | $45.62 | $17.23 |
Technical Indicators
Market Signals| Indicator | FRME | OGN |
|---|---|---|
| Relative Strength Index (RSI) | 62.08 | 82.71 |
| Support Level | $37.44 | $8.17 |
| Resistance Level | $39.03 | $9.64 |
| Average True Range (ATR) | 0.89 | 0.44 |
| MACD | 0.11 | 0.19 |
| Stochastic Oscillator | 84.30 | 95.10 |
Price Performance
Historical ComparisonAbout FRME First Merchants Corporation
First Merchants Corp, through its subsidiaries, provides its customers with financial services delivered locally by bankers. It offers personal banking, business banking, real estate mortgage lending, cash management services, brokerage, wealth management, and insurance. The company reports in only one segment which is community banking.
About OGN Organon & Co.
Organon & Co is a science-based pharmaceutical company that develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. The Company's operations include the following product portfolio: Women's health, Biosimilars and Established medicines. Geographically, it derives a majority of its revenue from Europe and Canada followed by the United States and then Asia Pacific and Japan. The company generates the majority of its revenue from the Established Brands product portfolio.